GC012F injection

DRUG13 trials

Sponsors

Shanghai Changzheng Hospital, Zhejiang University, RenJi Hospital, Gracell Biotechnologies (Shanghai) Co., Ltd., Chongbo Zhao

Conditions

CAR-TCAR-T Cell TherapyGeneralized Myasthenia Gravis (gMG)Idiopathic Inflammatory Myopathy (IIM)Multiple MyelomaRefractory Generalized Myasthenia GravisRefractory Systemic Lupus ErythematosusRelapsed/Refractory AL Amyloidosis

Early Phase 1

BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma

Shanghai Changzheng HospitalMultiple Myeloma

Start: 2020-01-16End: 2022-12-31Target: 15Updated: 2021-06-15

BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma

Shanghai Changzheng HospitalMultiple Myeloma

Start: 2021-12-01End: 2022-02-01Target: 15Updated: 2021-09-22

Study of FasT CAR-T GC012F Injection NDMM Patients

RecruitingNCT05840107

Shanghai Changzheng HospitalMultiple Myeloma

Start: 2023-05-04End: 2025-09-30Target: 18Updated: 2024-02-13

Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients

RecruitingNCT05858684

RenJi HospitalCAR-T Cell Therapy

Start: 2023-05-11End: 2029-06-10Target: 18Updated: 2026-06-01

An Exploratory Clinical Study of GC012F Injection for Refractory gMG

WithdrawnNCT06419166

Zhejiang UniversityRefractory Generalized Myasthenia Gravis

Start: 2024-12-01End: 2027-10-01Updated: 2025-06-27

GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)

RecruitingNCT07058298

Daishi TianGeneralized Myasthenia Gravis (gMG)

Start: 2025-07-15End: 2027-09-10Target: 6Updated: 2025-09-08

GC012F in Patients With Autoimmune Diseases

Not yet recruitingNCT07072884

Qiong FuIdiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc)

Start: 2025-08-18End: 2029-03-31Target: 15Updated: 2025-07-18

Phase 1

Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients

Shanghai Changzheng HospitalMultiple Myeloma

Start: 2021-06-28End: 2023-07-01Target: 20Updated: 2022-08-03

Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma

Shanghai Changzheng HospitalMultiple Myeloma

Start: 2022-06-13End: 2024-06-01Target: 9Updated: 2022-07-26

Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus Erythematosus

Zhejiang UniversityCAR-T

Start: 2023-05-15End: 2025-04-19Target: 15Updated: 2023-05-11

A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus

Active, not recruitingNCT06530849

Gracell Biotechnologies (Shanghai) Co., Ltd.Refractory Systemic Lupus Erythematosus

Start: 2024-08-22End: 2027-02-01Updated: 2026-09-09

An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis

Not yet recruitingNCT06759948

Chongbo ZhaoGeneralized Myasthenia Gravis (gMG)

Start: 2025-02-15End: 2027-09-10Target: 18Updated: 2025-01-06

Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

RecruitingNCT07250269

Gracell Biotechnologies (Shanghai) Co., Ltd.Relapsed/Refractory AL Amyloidosis

Start: 2025-10-29End: 2028-11-24Target: 9Updated: 2026-07-23

Related Papers

BCMA/CD19 dual-targeting CAR T cell therapy in older patients with newly diagnosed multiple myeloma: a phase I study.

2026-04-02

A dual targeting BCMA and CD19 fastcar-t (GC012F/AZD0120) as first-line therapy for newly diagnosed multiple myeloma

Blood2025-11-03

One-year follow-up of CD19/BCMA dual-targeting fastcar-T GC012F (AZD0120) therapy in patients with refractory systemic lupus erythematosus

Blood2025-11-03

Autologous B Cell Maturation Antigen (BCMA) and CD19 Dual Targeting Fastcar-T Cells (GC012F/AZD0120) As First-Line Therapy for Elderly Patients with Newly Diagnosed Multiple Myeloma Patients

Blood2024-11-052 citations

Updated Results of a Phase I Open-Label Single-Arm Study of Dual Targeting BCMA and CD19 Fastcar-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma

Blood2023-11-0220 citations

P869: UPDATED RESULTS OF A PHASE I, OPEN-LABEL STUDY OF BCMA/CD19 DUAL-TARGETING FASTCAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

HemaSphere2023-08-019 citations

Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM).

Journal of Clinical Oncology2023-06-0132 citations

Phase I Open-Label Single-Arm Study of BCMA/CD19 Dual-Targeting FasTCAR-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma

Blood2022-11-1516 citations

Updated results of a multicenter first-in-human study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM).

Journal of Clinical Oncology2022-06-0114 citations

S186: UPDATED RESULTS OF A MULTICENTER FIRST-IN-HUMAN STUDY OF BCMA/CD19 DUAL-TARGETING FAST CAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

HemaSphere2022-06-012 citations

Long-term follow-up results of a multicenter first-in-human study of the dual BCMA/CD19 Targeted FasT CAR-T GC012F for patients with relapsed/refractory multiple myeloma.

Journal of Clinical Oncology2021-05-2011 citations

Clinical Results of a Multicenter Study of the First-in-Human Dual BCMA and CD19 Targeted Novel Platform Fast CAR-T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma

Blood2020-11-0448 citations